Retrieve available abstracts of 159 articles: HTML format
Single Articles
May 2025
EASL Clinical Practice Guidelines on the management of autoimmune hepatitis.
J Hepatol. 2025 May 10:S0168-8278(25)00173-4. doi: 10.1016/j.jhep.2025. PubMedAbstract available
EASL Clinical Practice Guidelines on the management of hepatitis B virus
infection.
J Hepatol. 2025 May 8:S0168-8278(25)00174-6. doi: 10.1016/j.jhep.2025. PubMedAbstract available
SCHWARZ T, Ptok J, Damagnez M, Menne C, et al HBV shows different levels of adaptation to HLA class I-associated selection
pressure correlating with markers of replication.
J Hepatol. 2025;82:805-815. PubMedAbstract available
April 2025
HOUGHTON M A rat hepacivirus model to aid hepatitis C viral vaccine development ?
J Hepatol. 2025 Apr 16:S0168-8278(25)00243-0. doi: 10.1016/j.jhep.2025. PubMed
SANDMANN L Toward functional cure of hepatitis B: Is combination therapy the key?
J Hepatol. 2025 Apr 15:S0168-8278(25)00212-0. doi: 10.1016/j.jhep.2025. PubMed
FERNANDES FF, Ferreira da Silva PG, Villela Nogueira CA Follow-up NIT values rather than their variation predict hepatocellular carcinoma
after HCV eradication.
J Hepatol. 2025 Apr 12:S0168-8278(25)00237-5. doi: 10.1016/j.jhep.2025. PubMed
MONTES MG, Caraballo LL, Sousa Martin JM REPLY TO "UPDATE IN CLINICAL SCIENCE: AUTOIMMUNE HEPATITIS": USE OF
ENTERIC-COATED MYCOPHENOLATE SODIUM AS A THERAPEUTIC OPTION FOR AUTOIMMUNE
HEPATITIS.
J Hepatol. 2025 Apr 9:S0168-8278(25)00228-4. doi: 10.1016/j.jhep.2025. PubMed
CORMAN VM, Schwarz T, Steinmann E Rat hepatitis E virus: the new kid on the block?
J Hepatol. 2025 Apr 9:S0168-8278(25)00218-1. doi: 10.1016/j.jhep.2025. PubMed
LUHMANN N, Wedemeyer H More than 10 years of IFN-free HCV treatment and viral hepatitis elimination:
Mission not completed!
J Hepatol. 2025 Apr 8:S0168-8278(25)00220-X. doi: 10.1016/j.jhep.2025. PubMed
BUTI M, Riveiro-Barciela M, Forns X Rat Hepatitis E: A Silent Threat or Overestimated Risk?
J Hepatol. 2025 Apr 2:S0168-8278(25)00217-X. doi: 10.1016/j.jhep.2025. PubMed
JIN F, Gridley J, Kumari A, Saeidi A, et al Hyperfunctional T cell responses unchecked by regulatory T cells are unable to
resolve hepaciviral infection without humoral contribution.
J Hepatol. 2025;82:604-614. PubMedAbstract available
March 2025
THORSELIUS CE, Wolfisberg R, Fahnoe U, Scheel TKH, et al Norway rat hepacivirus resembles hepatitis C virus in terms of intra-host
evolution and escape from neutralizing antibodies.
J Hepatol. 2025 Mar 15:S0168-8278(25)00163-1. doi: 10.1016/j.jhep.2025. PubMedAbstract available
SANCHEZ-TORRIJOS Y, Fernandez-Alvarez P, Rosales JM, Perez-Estrada C, et al Recompensation of decompensated cirrhosis in hepatitis C patients after SVR:
Prognostic implications.
J Hepatol. 2025 Mar 6:S0168-8278(25)00153-9. doi: 10.1016/j.jhep.2025. PubMedAbstract available
February 2025
HUANG SC, Su TH Divergent Roles of MASLD Components in Chronic Hepatitis B: A Double-Edged Sword.
J Hepatol. 2025 Feb 28:S0168-8278(25)00144-8. doi: 10.1016/j.jhep.2025. PubMed
CABALLERO-GOMEZ J, Casares-Jimenez M, Gallo-Marin M, Pereira-Pardo S, et al Rat hepatitis E virus as an aetiological agent of acute hepatitis of unknown
origin.
J Hepatol. 2025 Feb 26:S0168-8278(25)00136-9. doi: 10.1016/j.jhep.2025. PubMedAbstract available
NAHON P, Lusivika-Nzinga C, Merle P, Zoulim F, et al Value of non-invasive test dynamics in guiding HCC surveillance decisions after
HCV cure in patients with cirrhosis.
J Hepatol. 2025 Feb 26:S0168-8278(25)00084-4. doi: 10.1016/j.jhep.2025. PubMedAbstract available
WANG J, Zhang S, Zhu C, Wu C, et al Treatment coverage of the 2024 updated WHO guidelines for patients with chronic
hepatitis B.
J Hepatol. 2025 Feb 8:S0168-8278(25)00077-7. doi: 10.1016/j.jhep.2025. PubMed
LAI JC, Cai J, Yip TC Reply to: "Evaluating Fracture Risk with TDF in Elderly Hepatitis B Patients: A
Korean Perspective".
J Hepatol. 2025 Feb 8:S0168-8278(25)00076-5. doi: 10.1016/j.jhep.2025. PubMed
RAZAVI HA, Waked I, Qureshi H, Kondili LA, et al Number of people treated for hepatitis C virus infection in 2014-2023 and
applicable lessons for new HBV and HDV therapies.
J Hepatol. 2025 Feb 4:S0168-8278(25)00020-0. doi: 10.1016/j.jhep.2025. PubMedAbstract available
LI F, Qu L, Liu Y, Wu X, et al PegIFN alpha-2a reduces relapse in HBeAg-negative patients after nucleo(s)tide
analogue cessation: A randomized-controlled trial.
J Hepatol. 2025;82:211-221. PubMedAbstract available
HAN Y, Tang J, Hu P, Ren H, et al Metabolic dysfunction-associated steatotic liver disease may increase
intrahepatic interferon gene signatures in patients with chronic hepatitis B.
J Hepatol. 2025 Feb 1:S0168-8278(25)00073-X. doi: 10.1016/j.jhep.2025. PubMed
January 2025
WANG J, Zhang S, Zhu C, Wu C, et al Increased HBsAg loss in HBeAg-negative patients with chronic hepatitis B and
concurrent MASLD.
J Hepatol. 2025 Jan 29:S0168-8278(25)00059-5. doi: 10.1016/j.jhep.2025. PubMed
HENEGHAN MA, Lohse AW Update in Clinical Science: Autoimmune Hepatitis.
J Hepatol. 2025 Jan 24:S0168-8278(24)02832-0. doi: 10.1016/j.jhep.2024. PubMedAbstract available
SANDMANN L Antiviral treatment of chronic hepatitis D virus infection: To combine or not to
combine?
J Hepatol. 2025 Jan 20:S0168-8278(24)02820-4. doi: 10.1016/j.jhep.2024. PubMed
December 2024
WAN-HIN HUI R, Mak LY, Yuen MF Reply to: "ALT to qHBsAg ratio predicts HBsAg seroclearance in HBeAg-negative
hepatitis B patients with Peg-IFNalpha based therapy".
J Hepatol. 2024 Dec 24:S0168-8278(24)02821-6. doi: 10.1016/j.jhep.2024. PubMed
SHIN H, Hur MH, Song BG, Park SY, et al AI model using CT-based imaging biomarkers to predict hepatocellular carcinoma in
patients with chronic hepatitis B.
J Hepatol. 2024 Dec 20:S0168-8278(24)02784-3. doi: 10.1016/j.jhep.2024. PubMedAbstract available
GAO G, Guo J, Yu G, Li GF, et al Long-term use of tenofovir disoproxil fumarate and increased fracture risk in
elderly patients with chronic hepatitis B: A Sensitivity Analysis Quantifying
Effect of Unmeasured Confounding factors on Observational Associations.
J Hepatol. 2024 Dec 17:S0168-8278(24)02777-6. doi: 10.1016/j.jhep.2024. PubMed
WANG C, Tian H, Shang J Assessment of methods in E1E2 versus E2 immunogen studies for HCV vaccine
research.
J Hepatol. 2024 Dec 17:S0168-8278(24)02778-8. doi: 10.1016/j.jhep.2024. PubMed
HUANG SC, Su TH, Tseng TC, Hsu SJ, et al All-cause and cause-specific mortality in patients with chronic hepatitis B and
concurrent steatotic liver disease.
J Hepatol. 2024 Dec 13:S0168-8278(24)02763-6. doi: 10.1016/j.jhep.2024. PubMedAbstract available
DEGASPERI E, Scholtes C, Testoni B, Renteria SU, et al Differential HBV RNA and HBcrAg patterns in untreated patients with chronic
hepatitis delta.
J Hepatol. 2024 Dec 9:S0168-8278(24)02759-4. doi: 10.1016/j.jhep.2024. PubMedAbstract available
LAI-HUNG WONG G, Lemoine M The 2024 updated WHO guidelines for the prevention and management of chronic
hepatitis B: main changes and potential implications for the next major liver
society clinical practice guidelines.
J Hepatol. 2024 Dec 6:S0168-8278(24)02755-7. doi: 10.1016/j.jhep.2024. PubMedAbstract available
November 2024
DONGELMANS EJ, Janssen HLA Reply to "The incidence of hepatitis flare and hepatic decompensation after
nucleos(t)ide analogue cessation in chronic hepatitis B patients.".
J Hepatol. 2024 Nov 29:S0168-8278(24)02746-6. doi: 10.1016/j.jhep.2024. PubMed
OKAMOTO T, Hatano E Reply to: "Could the paediatric acute hepatitis of unknown origin be related to a
new autoimmune disease?".
J Hepatol. 2024 Nov 29:S0168-8278(24)02747-8. doi: 10.1016/j.jhep.2024. PubMed
SHIN YE, Kim JY, Yoo JJ, Kim SG, et al Evaluating Fracture Risk with TDF in Elderly Hepatitis B Patients: A Korean
Perspective.
J Hepatol. 2024 Nov 20:S0168-8278(24)02722-3. doi: 10.1016/j.jhep.2024. PubMed
SHEN M, He S, Yao N, Li R, et al Real-world clinical data-driven modelling on the initiation time of antiviral
prophylaxis among pregnant women with chronic hepatitis B infection.
J Hepatol. 2024 Nov 20:S0168-8278(24)02717-X. doi: 10.1016/j.jhep.2024. PubMedAbstract available
CHE-TO LAI J, Wong GL, Tse YK, Hui VW, et al Histological severity, clinical outcomes and impact of antiviral treatment in
indeterminate phase of chronic hepatitis B: a systematic review and
meta-analysis.
J Hepatol. 2024 Nov 20:S0168-8278(24)02718-1. doi: 10.1016/j.jhep.2024. PubMedAbstract available
LIU Y, Wei Y, Chen X, Huang S, et al Genetic study of intrahepatic cholestasis of pregnancy in Chinese women unveils
East Asian etiology linked to historic HBV epidemic.
J Hepatol. 2024 Nov 13:S0168-8278(24)02708-9. doi: 10.1016/j.jhep.2024. PubMedAbstract available
HUR MH, Lee JH Reply to "A machine learning model to predict liver-related outcomes after the
functional cure of chronic hepatitis B: Is cirrhosis driving the performance?".
J Hepatol. 2024 Nov 8:S0168-8278(24)02700-4. doi: 10.1016/j.jhep.2024. PubMed
MON HC, Huang YH Reply to "Immune checkpoint inhibitor therapy for functional cure of hepatitis B
in cancer patients: a promising strategy?" and "Hepatocellular Carcinoma Patients
as an Ideal Study Population for Immune Checkpoint Inhibitors in Hepatitis B".
J Hepatol. 2024 Nov 8:S0168-8278(24)02701-6. doi: 10.1016/j.jhep.2024. PubMed
HUI RW, Mak LY, Yuen MF Reply to: "Community health strategies for chronic hepatitis B: Advancing care
with the ALT/qHBsAg ratio".
J Hepatol. 2024 Nov 6:S0168-8278(24)02657-6. doi: 10.1016/j.jhep.2024. PubMed
TONIUTTO P, Falleti E, Cmet S, Cussigh A, et al Sodium taurocholate cotransporting polypeptide (NTCP) polymorphisms may influence
HDV RNA load and early response to bulevirtide.
J Hepatol. 2024;81:819-826. PubMedAbstract available
October 2024
OSMANI Z, Brouwer WP, Grashof DGB, Lim Y, et al Metabolic dysfunction-associated steatohepatitis reduces interferon and
macrophage liver gene signatures in patients with chronic hepatitis B.
J Hepatol. 2024 Oct 26:S0168-8278(24)02653-9. doi: 10.1016/j.jhep.2024. PubMedAbstract available
LIU YC, Liaw YF The incidence of hepatitis flare and hepatic decompensation after nucleos(t)ide
analogue cessation in chronic hepatitis B patients.
J Hepatol. 2024 Oct 18:S0168-8278(24)02638-2. doi: 10.1016/j.jhep.2024. PubMed
CHEUK-FUNG YIP T, Peng N, Che-To Lai J Long-term use of tenofovir disoproxil fumarate increases fracture risk in elderly
patients with chronic hepatitis B - Reply to Di et al. and Huang et al.
J Hepatol. 2024 Oct 16:S0168-8278(24)02633-3. doi: 10.1016/j.jhep.2024. PubMed
WANG J, Zhang Q, Zhang S, Wu C, et al ALT to qHBsAg ratio predicts HBsAg seroclearance in HBeAg-negative hepatitis B
patients with Peg-IFN-alpha-based therapy.
J Hepatol. 2024 Oct 16:S0168-8278(24)02628-X. doi: 10.1016/j.jhep.2024. PubMed
XIAO G, Ren H Hepatocellular Carcinoma Patients as an Ideal Study Population for Immune
Checkpoint Inhibitors in Hepatitis B.
J Hepatol. 2024 Oct 16:S0168-8278(24)02630-8. doi: 10.1016/j.jhep.2024. PubMed
MARTINEZ-LASO J, Cervera I, Munoz M, Casas I, et al Could the paediatric acute hepatitis of unknown origin be related to a new
autoimmune disease?
J Hepatol. 2024 Oct 15:S0168-8278(24)02626-6. doi: 10.1016/j.jhep.2024. PubMed
SLOOTER CD, Stoelinga AEC, Snijders RJALM Reply to: Obtaining first-line induction in autoimmune hepatitis: aren't we
underestimating prednisolone?
J Hepatol. 2024 Oct 4:S0168-8278(24)02580-7. doi: 10.1016/j.jhep.2024. PubMed
LIU CH, Cheng PN, Fang YJ, Chen CY, et al Risk of de novo HCC in patients with MASLD following direct-acting
antiviral-induced cure of HCV infection.
J Hepatol. 2024 Oct 3:S0168-8278(24)02578-9. doi: 10.1016/j.jhep.2024. PubMedAbstract available
PAPATHEODORIDI M, De Ledinghen V, Lupsor-Platon M, Bronte F, et al Agile scores in MASLD and ALD: External validation and their utility in clinical
algorithms.
J Hepatol. 2024;81:590-599. PubMedAbstract available
WEDEMEYER H, Aleman S, Brunetto M, Blank A, et al Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety results
through week 96 from a phase III randomized trial.
J Hepatol. 2024;81:621-629. PubMedAbstract available
September 2024
CUI Y Community Health Strategies for Chronic Hepatitis B: Advancing Care with the
ALT/qHBsAg Ratio.
J Hepatol. 2024 Sep 30:S0168-8278(24)02575-3. doi: 10.1016/j.jhep.2024. PubMed
LUO J, Gao B, Li B Immune checkpoint inhibitor therapy for functional cure of hepatitis B in cancer
patients: a promising strategy?
J Hepatol. 2024 Sep 27:S0168-8278(24)02571-6. doi: 10.1016/j.jhep.2024. PubMed
LIN H, Cheuk-Fung Yip T, Lee HW, Meng X, et al AI-Safe-C Score: Assessing Liver-Related Event Risks in Non-Cirrhotic Patients
after Successful Direct-Acting Antiviral Treatment.
J Hepatol. 2024 Sep 20:S0168-8278(24)02560-1. doi: 10.1016/j.jhep.2024. PubMedAbstract available
XIAO G, Ren H A machine learning model to predict liver-related outcomes after the functional
cure of chronic hepatitis B: Is cirrhosis driving the performance?
J Hepatol. 2024 Sep 19:S0168-8278(24)02556-X. doi: 10.1016/j.jhep.2024. PubMed
CHUNG CY, Wang SH, Yeh SH, Chen PJ, et al Reply to: Hepatitis B Virus spliced 1 RNA, a key factor for viral expression.
J Hepatol. 2024 Sep 10:S0168-8278(24)02545-5. doi: 10.1016/j.jhep.2024. PubMed
WU JL, Luo JY, Jiang ZB Association between antiviral treatments and fracture in elderly patients with
HBV needs further evaluation.
J Hepatol. 2024;81:e108-e109. PubMed
August 2024
DONGELMANS EJ, Hirode G, Hansen BE, Chen CH, et al Predictors of hepatic flares after nucleos(t)ide analogue cessation - Results of
a global cohort study (RETRACT-B study).
J Hepatol. 2024 Aug 31:S0168-8278(24)02493-0. doi: 10.1016/j.jhep.2024. PubMedAbstract available
KUDARAVALLI S, Henry L, Nguyen MH Integrating Strategic, Equity, and Socioeconomic Perspectives: A Holistic
Approach to Advancing Hepatitis B Management and Outcomes.
J Hepatol. 2024 Aug 30:S0168-8278(24)02491-7. doi: 10.1016/j.jhep.2024. PubMed
HUR MH, Yip TC, Kim SU, Lee HW, et al A machine learning model to predict liver-related outcomes after the functional
cure of chronic hepatitis B.
J Hepatol. 2024 Aug 30:S0168-8278(24)02494-2. doi: 10.1016/j.jhep.2024. PubMedAbstract available
BUTI M, Heo J, Tanaka Y, Andreone P, et al Sequential Peg-IFN after bepirovirsen may reduce post-treatment relapse in
chronic hepatitis B.
J Hepatol. 2024 Aug 28:S0168-8278(24)02488-7. doi: 10.1016/j.jhep.2024. PubMedAbstract available
KIM SY, Shin EC Reply to: "Regulatory T cells dynamics during and after chronic hepatitis C
treatment".
J Hepatol. 2024 Aug 19:S0168-8278(24)02476-0. doi: 10.1016/j.jhep.2024. PubMed
CUI A, Chung RT, Alatrakchi N Changes of hepatic myeloid cells in chronic viral hepatitis and after cure and
their clinical significance - Reply.
J Hepatol. 2024 Aug 19:S0168-8278(24)02474-7. doi: 10.1016/j.jhep.2024. PubMed
July 2024
LOEFFEN EAH, Verkade HJ, van Rheenen PF Obtaining first-line induction in autoimmune hepatitis: aren't we underestimating
prednisolone?
J Hepatol. 2024 Jul 30:S0168-8278(24)02427-9. doi: 10.1016/j.jhep.2024. PubMed
WANG Y, Guo X, Yuan Y Addressing Bias and Improving Research on Gender and Racial Disparities in
Hepatitis B Assessment and Treatment.
J Hepatol. 2024 Jul 30:S0168-8278(24)02428-0. doi: 10.1016/j.jhep.2024. PubMed
VENZIN V, Beccaria CG, Andreata F, Fumagalli V, et al Intrahepatic immunity to hepatitis B virus.
J Hepatol. 2024 Jul 30:S0168-8278(24)00364-7. doi: 10.1016/j.jhep.2024. PubMed
MON HC, Lee PC, Hung YP, Hung YW, et al Functional cure of hepatitis B in patients with cancer undergoing immune
checkpoint inhibitor therapy.
J Hepatol. 2024 Jul 29:S0168-8278(24)02425-5. doi: 10.1016/j.jhep.2024. PubMedAbstract available
DI J, Song L, Xiang C Synergy between public health policy and clinicians plays a key role in reducing
fracture risk in patients with viral hepatitis.
J Hepatol. 2024 Jul 27:S0168-8278(24)02431-0. doi: 10.1016/j.jhep.2024. PubMed
SOLIMAN R, Hassan A, Shiha G Regulatory T Cells dynamics during and after Chronic Hepatitis C treatment.
J Hepatol. 2024 Jul 20:S0168-8278(24)02417-6. doi: 10.1016/j.jhep.2024. PubMed
RUI F, Ni W, Shi J, Xie Q, et al Superior Diagnostic Efficacy of AGILE 3+ Score for Diagnosing Advanced Fibrosis
in Chronic Hepatitis B patients with Concurrent Metabolic Dysfunction-Associated
Steatotic Liver Disease.
J Hepatol. 2024 Jul 20:S0168-8278(24)02416-4. doi: 10.1016/j.jhep.2024. PubMed
BUTI M, Wedemeyer H, Aleman S, Chulanov V, et al Patient-reported outcomes in chronic hepatitis delta: An exploratory analysis of
the Phase III MYR301 trial of bulevirtide.
J Hepatol. 2024 Jul 13:S0168-8278(24)02337-7. doi: 10.1016/j.jhep.2024. PubMedAbstract available
MINAMI T, Fujishiro M, Tateishi R Reply to: "Validation of SMART Model for HCC Risk stratification in genotype -4
HCV Patients following SVR and its comparison with GES score".
J Hepatol. 2024 Jul 9:S0168-8278(24)02361-4. doi: 10.1016/j.jhep.2024. PubMed
ZHANG JW, Lai RM, Wang LF, Wang SL, et al Varied immune responses of HBV-specific B cells in patients undergoing pegylated
interferon-alpha treatment for chronic hepatitis B.
J Hepatol. 2024 Jul 9:S0168-8278(24)02338-9. doi: 10.1016/j.jhep.2024. PubMedAbstract available
KUNDU J, Le HT, Logan M, Hockman D, et al Recombinant H77C gpE1/gpE2 heterodimer elicits superior HCV cross-neutralisation
than H77C gpE2 alone.
J Hepatol. 2024 Jul 8:S0168-8278(24)02335-3. doi: 10.1016/j.jhep.2024. PubMedAbstract available
TAK WY, Chuang WL, Chen CY, Tseng KC, et al Phase 1b/2a randomized study of heterologous ChAdOx1-HBV/MVA-HBV therapeutic
vaccination (VTP-300) as monotherapy and combined with low-dose nivolumab in
virally-suppressed patients with chronic hepatitis B.
J Hepatol. 2024 Jul 5:S0168-8278(24)02333-X. doi: 10.1016/j.jhep.2024. PubMedAbstract available
ZOULIM F, Chen PJ, Dandri M, Kennedy P, et al Hepatitis B Virus DNA integration: Implications for diagnostics, therapy, and
outcome.
J Hepatol. 2024 Jul 4:S0168-8278(24)02343-2. doi: 10.1016/j.jhep.2024. PubMedAbstract available
KUDARAVALLI S, Huang DQ, Yeh ML, Trinh L, et al Sex and ethnic disparities in hepatitis B evaluation and treatment across the
world.
J Hepatol. 2024;81:33-41. PubMedAbstract available
RICCO G, Brunetto MR Reply to: "Increase in HDV replication during steroid therapy - potential
implications for testing and treatment strategies".
J Hepatol. 2024;81:e51-e53. PubMed
GHANY MG, Buti M, Lampertico P, Lee HM, et al Reply to: "Ultrasensitive HBsAg testing predicts HBsAg seroreversion outcomes:
Considerations for new and existing therapies".
J Hepatol. 2024;81:e26-e27. PubMed
ANDERSON M, Holzmayer V, Stec M, Cloherty G, et al Ultrasensitive HBsAg testing predicts HBsAg seroreversion outcomes:
Considerations for new and existing therapies.
J Hepatol. 2024;81:e24-e25. PubMed
PATMORE LA, van der Eijk AA, Janssen HLA, de Man RA, et al Increase in HDV replication during steroid therapy - potential implications for
testing and treatment strategies.
J Hepatol. 2024;81:e49-e50. PubMed
YU H, Ren J, Deng H, Li L, et al Neuropilin-1 is a novel host factor modulating the entry of hepatitis B virus.
J Hepatol. 2024 Jul 1:S0168-8278(24)02339-0. doi: 10.1016/j.jhep.2024. PubMedAbstract available
June 2024
SLOOTER CD, Stoelinga AEC, Snijders RJALM Reply: Mycophenolate Mofetil in Autoimmune Hepatitis: Are We Ready for Primetime?
J Hepatol. 2024 Jun 15:S0168-8278(24)02318-3. doi: 10.1016/j.jhep.2024. PubMed
ZHANG H, Huang J, Zhu W, Feng W, et al Does long-term use of tenofovir disoproxil fumarate affect fracture risk in
patients with chronic hepatitis B?
J Hepatol. 2024 Jun 13:S0168-8278(24)02308-0. doi: 10.1016/j.jhep.2024. PubMed
KIM SY, Koh JY, Lee DH, Kim HD, et al Epigenetic scars in regulatory T cells are retained after successful treatment of
chronic hepatitis C with direct-acting antivirals.
J Hepatol. 2024 Jun 13:S0168-8278(24)02317-1. doi: 10.1016/j.jhep.2024. PubMedAbstract available
PATMORE LA, Sonneveld MJ Reply 'Exploring hepatocellular carcinoma risks in sub-Saharan African and
Afro-Surinamese individuals with chronic hepatitis B living in Europe'.
J Hepatol. 2024 Jun 11:S0168-8278(24)02311-0. doi: 10.1016/j.jhep.2024. PubMed
CHUNG CY, Sun CP, Tao MH, Wu HL, et al Major HBV splice variant encoding a novel protein important for infection.
J Hepatol. 2024;80:858-867. PubMedAbstract available
XU M, Warner C, Duan X, Cheng Z, et al HIV coinfection exacerbates HBV-induced liver fibrogenesis through a HIF-1alpha- and
TGF-beta1-dependent pathway.
J Hepatol. 2024;80:868-881. PubMedAbstract available
May 2024
REIBERGER T, Lens S, Cabibbo G, Nahon P, et al EASL position paper on clinical follow-up after HCV cure.
J Hepatol. 2024 May 30:S0168-8278(24)00275-7. doi: 10.1016/j.jhep.2024. PubMedAbstract available
MCCOULLOUGH LC, Fareh M, Hu W, Sozzi V, et al CRISPR-Cas13b-mediated suppression of hepatitis B virus replication and protein
expression.
J Hepatol. 2024 May 28:S0168-8278(24)00360-X. doi: 10.1016/j.jhep.2024. PubMedAbstract available
ZHANG Y, Zhou Y Enhancing Hepatitis B Management: The Role of Political, Economic, and
Educational Considerations in Addressing Global Disparities.
J Hepatol. 2024 May 24:S0168-8278(24)00357-X. doi: 10.1016/j.jhep.2024. PubMed
LI H, Guo Q, Guo C A Strategic Approach: Three-Tiered Management for Enhancing Global Hepatitis B
Outcomes.
J Hepatol. 2024 May 22:S0168-8278(24)00358-1. doi: 10.1016/j.jhep.2024. PubMed
GOMEZ-MORENO A, Guo J, Temple HM, Ploss A, et al Formation and transcriptional regulation of hepatitis B virus covalently closed
circular DNA.
J Hepatol. 2024 May 22:S0168-8278(24)00159-4. doi: 10.1016/j.jhep.2024. PubMed
CHAPUS F, Giraud G, Huchon P, Roda M, et al Helicases DDX5 and DDX17 promote heterogeneity in HBV transcription termination
in infected human hepatocytes.
J Hepatol. 2024 May 21:S0168-8278(24)00351-9. doi: 10.1016/j.jhep.2024. PubMedAbstract available
COLAPIETRO F, Lleo A Reply: Incidence And Predictors Of Hepatocellular Carcinoma In Patients With
Autoimmune Hepatitis?
J Hepatol. 2024 May 20:S0168-8278(24)00354-4. doi: 10.1016/j.jhep.2024. PubMed
LAI JC, Yip TC, Wong GL Long-term use of tenofovir disoproxil fumarate increases fracture risk in elderly
patients with chronic hepatitis B - Reply to Wu et al.
J Hepatol. 2024 May 17:S0168-8278(24)00344-1. doi: 10.1016/j.jhep.2024. PubMed
WEN Z Enhancing the understanding of the risk of incident fracture in entecavir- and
TDF-treated elderly patients with chronic hepatitis B (CHB).
J Hepatol. 2024 May 16:S0168-8278(24)00347-7. doi: 10.1016/j.jhep.2024. PubMed
SHIHA G, Mikhail N, Soliman R Validation of SMART Model for HCC Risk stratification in genotype -4 HCV Patients
following SVR and its comparison with GES score.
J Hepatol. 2024 May 15:S0168-8278(24)00348-9. doi: 10.1016/j.jhep.2024. PubMed
BABLON P, Goy C, Dang HN, Sotty J, et al Hepatitis B Virus spliced 1 RNA, a key factor for viral expression.
J Hepatol. 2024 May 9:S0168-8278(24)00331-3. doi: 10.1016/j.jhep.2024. PubMed
YANG F, Fan X, Zhou L, Yang L, et al Need for risk stratification in treatment of patients with autoimmune hepatitis.
J Hepatol. 2024 May 9:S0168-8278(24)00338-6. doi: 10.1016/j.jhep.2024. PubMed
VAN OORSCHOT E, Koc OM, Koek GH Osteoporosis in hepatitis B patients receiving tenofovir disoproxil fumarate:
does fibroblast growth factor 23 play a role?
J Hepatol. 2024 May 2:S0168-8278(24)00323-4. doi: 10.1016/j.jhep.2024. PubMed
QI R, Fu R, Lei X, He J, et al Therapeutic vaccine-induced plasma cell differentiation is defective in the
presence of persistently high HBsAg levels.
J Hepatol. 2024;80:714-729. PubMedAbstract available
April 2024
HEGARTY R, Hadzic N GENOMIC TESTING FOR INBORN ERRORS OF IMMUNITY IN SERONEGATIVE AUTOIMMUNE
HEPATITIS OF CHILDHOOD.
J Hepatol. 2024 Apr 26:S0168-8278(24)00289-7. doi: 10.1016/j.jhep.2024. PubMed
TAN MY, Su JH Exploring Hepatocellular Carcinoma Risks in Sub-Saharan African and
Afro-Surinamese Individuals with Chronic Hepatitis B living in Europe.
J Hepatol. 2024 Apr 26:S0168-8278(24)00287-3. doi: 10.1016/j.jhep.2024. PubMed
KENNEDY MJ, Fernbach S, Scheel TKH Animal hepacivirus models for hepatitis C virus immune responses and pathology.
J Hepatol. 2024 Apr 24:S0168-8278(23)05373-4. doi: 10.1016/j.jhep.2023. PubMed
UNDERWOOD AP, Gupta M, Wu BR, Eltahla AA, et al B cell characteristics define HCV reinfection outcome.
J Hepatol. 2024 Apr 9:S0168-8278(24)00271-X. doi: 10.1016/j.jhep.2024. PubMedAbstract available
AGARWAL K, Buti M, van Bommel F, Lampertico P, et al JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analog suppressed
patients with chronic hepatitis B: REEF-2.
J Hepatol. 2024 Apr 5:S0168-8278(24)00231-9. doi: 10.1016/j.jhep.2024. PubMedAbstract available
KONDILI LA, Lazarus JV, Jepsen P, Murray F, et al Inequities in primary liver cancer in Europe: The state of play.
J Hepatol. 2024;80:645-660. PubMedAbstract available
March 2024
BJORNSSON ES, Lucena MI, Andrade RJ Reply to the Letter to the Editor: Distinction of Autoimmune Hepatitis from Drug
Induced Autoimmune Like Hepatitis: The Answer Lies at the Interface.
J Hepatol. 2024 Mar 28:S0168-8278(24)00221-6. doi: 10.1016/j.jhep.2024. PubMed
SNIJDERS RJALM, Stoelinga AEC, van Hoek B, Drenth JPH, et al Prednisolone with azathioprine or mycophenolate mofetil as first-line therapy in
autoimmune hepatitis: insights from a randomized controlled trial.
J Hepatol. 2024 Mar 28:S0168-8278(24)00222-8. doi: 10.1016/j.jhep.2024. PubMed
HIN-MAN LEUNG R, Wan-Hin Hui R, Mak LY, Mao X, et al ALT to qHBsAg ratio predicts long-term HBsAg seroclearance after entecavir
cessation in Chinese patients with chronic hepatitis B.
J Hepatol. 2024 Mar 23:S0168-8278(24)00204-6. doi: 10.1016/j.jhep.2024. PubMedAbstract available
PASTA A, Pieri G, Plaz Torres MC, Trevisani F, et al Hepatocellular carcinoma in patients with Autoimmune Hepatitis.
J Hepatol. 2024 Mar 23:S0168-8278(24)00208-3. doi: 10.1016/j.jhep.2024. PubMed
PLAGIANNAKOS CG, Hirschfield GM, Lytvyak E, Roberts SB, et al Treatment response and clinical event-free survival in autoimmune hepatitis: a
Canadian multicentre cohort study.
J Hepatol. 2024 Mar 23:S0168-8278(24)00205-8. doi: 10.1016/j.jhep.2024. PubMedAbstract available
SEMMLER G, Alonso Lopez S, Pons M, Lens S, et al Post-treatment LSM rather than change during treatment predicts decompensation in
patients with cACLD after HCV cure.
J Hepatol. 2024 Mar 21:S0168-8278(24)00198-3. doi: 10.1016/j.jhep.2024. PubMedAbstract available
BISWAS S, Shalimar Mycophenolate Mofetil in Autoimmune Hepatitis: Are We Ready for Primetime?
J Hepatol. 2024 Mar 20:S0168-8278(24)00201-0. doi: 10.1016/j.jhep.2024. PubMed
TONNERRE P, Baumert TF Unraveling the liver antiviral immunity in functional cure of chronic hepatitis B
using scRNASeq.
J Hepatol. 2024 Mar 19:S0168-8278(24)00200-9. doi: 10.1016/j.jhep.2024. PubMed
THURSZ M, Mathurin P Targeting IL-1 in severe alcohol-related hepatitis; how many frogs will we need
to kiss to find an effective therapy?
J Hepatol. 2024 Mar 16:S0168-8278(24)00163-6. doi: 10.1016/j.jhep.2024. PubMed
JACHS M, Sandmann L, Hartl L, Tergast T, et al Validation of Baveno VII criteria and other non-invasive diagnostic algorithms
for clinically significant portal hypertension in hepatitis delta.
J Hepatol. 2024 Mar 11:S0168-8278(24)00156-9. doi: 10.1016/j.jhep.2024. PubMedAbstract available
SEITZ S, Bartenschlager R Cutting edges in the hepatitis B virus genome: How RNA splicing is involved in
modulating virus ultrastructure to promote infection.
J Hepatol. 2024 Mar 7:S0168-8278(24)00148-X. doi: 10.1016/j.jhep.2024. PubMed
SIMSEK C, Wahlin S, Efe C Autoimmune Hepatitis: Mycophenolate mofetil versus azathioprine as first line
therapy.
J Hepatol. 2024 Mar 6:S0168-8278(24)00142-9. doi: 10.1016/j.jhep.2024. PubMed
SHEEHAN Y, Grebely J, Lloyd AR Reply to: " 'One-stop-shop' point-of-care hepatitis C RNA testing intervention in
the prison - some issues".
J Hepatol. 2024;80:e107-e108. PubMed
February 2024
NARMADA BC, Khakpoor A, Shirgaonkar N, Narayanan S, et al Single cell landscape of functionally cured chronic hepatitis B patients reveals
activation of innate and altered CD4-CTL-driven adaptive immunity.
J Hepatol. 2024 Feb 27:S0168-8278(24)00137-5. doi: 10.1016/j.jhep.2024. PubMedAbstract available
ALRIC L Should MMF treatment be the first-line therapy in autoimmune hepatitis?
J Hepatol. 2024 Feb 23:S0168-8278(24)00134-X. doi: 10.1016/j.jhep.2024. PubMed
TIWARI A, Khanikar D, Rathod SG "Autoimmune Hepatitis: Azathioprine or Mycophenolate Mofetil for inducing
remission?".
J Hepatol. 2024 Feb 23:S0168-8278(24)00132-6. doi: 10.1016/j.jhep.2024. PubMed
BIALLAS R, Zimmermann R, Dudareva S Reply to: Population-based screening works: Effect of integrating screening for
hepatitis B and C into the general health check-up in Germany.
J Hepatol. 2024 Feb 23:S0168-8278(24)00133-8. doi: 10.1016/j.jhep.2024. PubMed
YANG H, Jang JW Reply to: 'A risk prediction model for hepatocellular carcinoma after hepatitis B
surface antigen seroclearance: Need a closer look!'.
J Hepatol. 2024 Feb 10:S0168-8278(24)00123-5. doi: 10.1016/j.jhep.2024. PubMed
GAWRIEH S, Dasarathy S, Tu W, Kamath PS, et al Randomized-controlled trial of anakinra plus zinc vs. prednisone for severe
alcohol-associated hepatitis.
J Hepatol. 2024 Feb 9:S0168-8278(24)00109-0. doi: 10.1016/j.jhep.2024. PubMedAbstract available
ALLWEISS L, Volmari A, Suri V, Wallin JJ, et al Blocking viral entry with bulevirtide reduces the number of HDV-infected
hepatocytes in human liver biopsies.
J Hepatol. 2024 Feb 8:S0168-8278(24)00114-4. doi: 10.1016/j.jhep.2024. PubMedAbstract available
LIU C, Guo C, Liu K Changes of hepatic myeloid cells in chronic viral hepatitis and after cure and
their clinical significance.
J Hepatol. 2024 Feb 6:S0168-8278(24)00121-1. doi: 10.1016/j.jhep.2024. PubMed
HEUSCHKEL MJ, Bach C, Meiss-Heydmann L, Gerges E, et al JAK1 promotes HDV replication and is a potential target for antiviral therapy.
J Hepatol. 2024;80:220-231. PubMedAbstract available
HIRSCHFIELD GM, Lohse AW Editorial: Treating Autoimmune Hepatitis - more science, more progress, better
therapy.
J Hepatol. 2024 Feb 1:S0168-8278(24)00098-9. doi: 10.1016/j.jhep.2024. PubMed
ALKASHASH A, Zhang X, Vuppalanchi R, Lammert C, et al Distinction of Autoimmune Hepatitis from Drug Induced Autoimmune Like Hepatitis:
The Answer Lies at the Interface.
J Hepatol. 2024 Feb 1:S0168-8278(24)00100-4. doi: 10.1016/j.jhep.2024. PubMed
January 2024
FAN X, Yang F, Zhou L, Yang L, et al Mycophenolate mofetil for the induction of remission in primary biliary
cholangitis with predominant features of autoimmune hepatitis.
J Hepatol. 2024 Jan 31:S0168-8278(24)00097-7. doi: 10.1016/j.jhep.2024. PubMed
HEO M, Norton BL, Pericot-Valverde I, Mehta SH, et al Optimal Hepatitis C Treatment Adherence Patterns and Sustained Virologic
Response. among People Who Inject Drugs: The HERO Study.
J Hepatol. 2024 Jan 17:S0168-8278(23)05374-6. doi: 10.1016/j.jhep.2023. PubMedAbstract available
HACHICHA-MAALEJ N, Collins IJ, Ades AE, Scott K, et al Corrigendum to "Modelling the potential effectiveness of hepatitis C screening
and treatment strategies during pregnancy in Egypt and Ukraine" [J Hepatol (2023)
937-946].
J Hepatol. 2024 Jan 4:S0168-8278(23)05367-9. doi: 10.1016/j.jhep.2023. PubMed
THOMPSON LA, Charlton CL Evaluation and comparison of risk-based and universal HCV screening programs.
J Hepatol. 2024 Jan 3:S0168-8278(24)00005-9. doi: 10.1016/j.jhep.2023. PubMed
ZHANG Y, Bourgine M, Wan Y, Song J, et al Therapeutic vaccination with lentiviral vector in HBV-persistent mice and two
inactive HBsAg carriers.
J Hepatol. 2024;80:31-40. PubMedAbstract available
TROVATO FM, McPhail M Reply to: "Dysregulation of the LPC-ATX-LPA axis in autoimmune hepatitis is
associated with monocyte activation": Autotaxin upregulation in liver failure and
the effect on monocyte phenotype and function is a pan-aetiology phenomenon.
J Hepatol. 2024;80:e16-e18. PubMed
December 2023
CSERNALABICS B, Marinescu MS, Maurer L, Kelsch L, et al Efficient formation and maintenance of humoral and CD4 T cell immunity targeting
the viral capsid in acute-resolving hepatitis E infection.
J Hepatol. 2023 Dec 26:S0168-8278(23)05370-9. doi: 10.1016/j.jhep.2023. PubMedAbstract available
VAN BOMMEL F, Berg T Response to: A comment on "A multicenter randomized-controlled trial of
nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B.".
J Hepatol. 2023 Dec 16:S0168-8278(23)05356-4. doi: 10.1016/j.jhep.2023. PubMed
CHE-TO LAI J, Lai-Hung Wong G, Wai-Sun Wong V, Cheuk-Fung Yip T, et al Unmet need in screening for hepatitis D virus: time to take action.
J Hepatol. 2023 Dec 16:S0168-8278(23)05360-6. doi: 10.1016/j.jhep.2023. PubMed
SNIJDERS RJ, Stoelinga AE, Gevers TJ, Pape S, et al An open-label randomised-controlled trial of azathioprine vs. mycophenolate
mofetil for the induction of remission in treatment-naive autoimmune hepatitis.
J Hepatol. 2023 Dec 13:S0168-8278(23)05309-6. doi: 10.1016/j.jhep.2023. PubMedAbstract available
CHEUK-FUNG YIP T, Che-To Lai J, Yam TF, Tse YK, et al Long-term use of tenofovir disoproxil fumarate increases fracture risk in elderly
patients with chronic hepatitis B.
J Hepatol. 2023 Dec 13:S0168-8278(23)05354-0. doi: 10.1016/j.jhep.2023. PubMedAbstract available
November 2023
COLASANTI O, Burm R, Huang HE, Riedl T, et al Corrigendum to "Comparison of HAV and HCV infections in vivo and in vitro reveals
distinct patterns of innate immune evasion and activation" [J Hepatol (2023)
645-656].
J Hepatol. 2023 Nov 30:S0168-8278(23)05282-0. doi: 10.1016/j.jhep.2023. PubMed
The adjusted prevalence of hepatitis delta virus (HDV) in 25 countries and
territories.
J Hepatol. 2023 Nov 27:S0168-8278(23)05285-6. doi: 10.1016/j.jhep.2023. PubMedAbstract available
BALAGOPAL A, Thomas DL Genomics on the road to functional cure of hepatitis B.
J Hepatol. 2023 Nov 18:S0168-8278(23)05276-5. doi: 10.1016/j.jhep.2023. PubMed
HUPPE D, Wedemeyer H, Cornberg M Population-based screening works: Effect of integrating screening for hepatitis B
and C into the general health check-up in Germany.
J Hepatol. 2023 Nov 3:S0168-8278(23)05234-0. doi: 10.1016/j.jhep.2023. PubMed
October 2023
PATMORE LA, van Eekhout KMA, Buti M, Koc OM, et al Hepatocellular carcinoma risk in Sub-Saharan African and Afro-Surinamese
individuals with chronic hepatitis B living in Europe.
J Hepatol. 2023 Oct 26:S0168-8278(23)05219-4. doi: 10.1016/j.jhep.2023. PubMedAbstract available
MURRAY SM, Pose E, Wittner M, Londono MC, et al Immune responses and clinical outcomes after COVID-19 vaccination in patients
with liver disease and in liver transplant recipients.
J Hepatol. 2023 Oct 18:S0168-8278(23)05174-7. doi: 10.1016/j.jhep.2023. PubMedAbstract available
GUAN G, Zhang T, Ning J, Tao C, et al Higher TP53BP2 expression is associated with HBsAg loss in
peginterferon-alpha-treated patients with chronic hepatitis B.
J Hepatol. 2023 Oct 17:S0168-8278(23)05175-9. doi: 10.1016/j.jhep.2023. PubMedAbstract available
PANDURANGI S, Malik A, Owens J, Valencia CA, et al Deleterious variants in TNFAIP3 are associated with type II and seronegative
Pediatric autoimmune hepatitis.
J Hepatol. 2023 Oct 9:S0168-8278(23)05156-5. doi: 10.1016/j.jhep.2023. PubMed
GRONBAEK L, Gronbaek H Editorial: Hepatocellular carcinoma in autoimmune hepatitis remains rare.
J Hepatol. 2023 Oct 9:S0168-8278(23)05159-0. doi: 10.1016/j.jhep.2023. PubMed
COLAPIETRO F, Maisonneuve P, Lytvyak E, Beuers U, et al Incidence and predictors of hepatocellular carcinoma in patients with autoimmune
hepatitis.
J Hepatol. 2023 Oct 4:S0168-8278(23)05095-X. doi: 10.1016/j.jhep.2023. PubMedAbstract available
LU W A risk prediction model for hepatocellular carcinoma after hepatitis B surface
antigen seroclearance: Need a closer look!
J Hepatol. 2023 Oct 3:S0168-8278(23)05142-5. doi: 10.1016/j.jhep.2023. PubMed
September 2023
CHUN HS, Papatheodoridis GV, Lee M, Lee HA, et al PAGE-B incorporating moderate HBV DNA levels predicts risk of HCC among patients
entering into HBeAg-positive chronic hepatitis B.
J Hepatol. 2023 Sep 19:S0168-8278(23)05096-1. doi: 10.1016/j.jhep.2023. PubMedAbstract available
June 2023
MINAMI T, Sato M, Toyoda H, Yasuda S, et al Machine learning for individualized prediction of hepatocellular carcinoma
development after the eradication of hepatitis C virus with antivirals.
J Hepatol. 2023 Jun 24:S0168-8278(23)00424-5. doi: 10.1016/j.jhep.2023. PubMedAbstract available
FAN R, Chen L, Zhao S, Yang H, et al Novel, high accuracy models for hepatocellular carcinoma prediction based on
longitudinal data and cell-free DNA signatures.
J Hepatol. 2023 Jun 9:S0168-8278(23)00416-6. doi: 10.1016/j.jhep.2023. PubMedAbstract available
March 2023
GANE EJ, Dunbar PR, Brooks AE, Zhang F, et al Safety and efficacy of the oral TLR8 agonist selgantolimod in individuals with
chronic hepatitis B under viral suppression.
J Hepatol. 2023;78:513-523. PubMedAbstract available